Insmed lung disease drug hits target in key Phase 3 trial biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ Insmed Incorporated , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today.
/PRNewswire/ Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare.
Truist Financial restated their buy rating on shares of Insmed (NASDAQ:INSM – Free Report) in a report released on Thursday, Benzinga reports. The firm currently has a $48.00 price objective on the biopharmaceutical company’s stock. A number of other research analysts have also recently issued reports on INSM. UBS Group began coverage on Insmed in […]